Fallopian Tube Cancer - Pipeline Review, H1 2020

April 2020 | 1496 pages | ID: F5883E25EFBEN
Global Markets Direct

Abstracts

Fallopian Tube Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2020, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 20, 72, 52, 2, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 8 and 1 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Fallopian Tube Cancer - Overview
Fallopian Tube Cancer - Therapeutics Development
Fallopian Tube Cancer - Therapeutics Assessment
Fallopian Tube Cancer - Companies Involved in Therapeutics Development
Fallopian Tube Cancer - Drug Profiles
Fallopian Tube Cancer - Dormant Projects
Fallopian Tube Cancer - Discontinued Products
Fallopian Tube Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Fallopian Tube Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Fallopian Tube Cancer - Pipeline by AB Science SA, H1 2020
Fallopian Tube Cancer - Pipeline by AbbVie Inc, H1 2020
Fallopian Tube Cancer - Pipeline by ADC Therapeutics SA, H1 2020
Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
Fallopian Tube Cancer - Pipeline by AiVita Biomedical Inc, H1 2020
Fallopian Tube Cancer - Pipeline by Aldeyra Therapeutics Inc, H1 2020
Fallopian Tube Cancer - Pipeline by Amgen Inc, H1 2020
Fallopian Tube Cancer - Pipeline by Anew Oncology Inc, H1 2020
Fallopian Tube Cancer - Pipeline by Apexigen Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fallopian Tube Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AB Science SA
AbbVie Inc
ADC Therapeutics SA
Advenchen Laboratories LLC
AiVita Biomedical Inc
Aldeyra Therapeutics Inc
Amgen Inc
Anew Oncology Inc
Apexigen Inc
Apollomics Inc
Apotex Inc
Aravive Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
BioIntegrator Ltd
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Celldex Therapeutics Inc
Celsion Corp
Celyad SA
Chipscreen Biosciences Ltd
Clovis Oncology Inc
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Cristal Therapeutics BV
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
ENB Therapeutics LLC
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Gene Techno Science Co Ltd
Genentech Inc
Genmab AS
Gilead Sciences Inc
GlaxoSmithKline Plc
Gradalis Inc
I-Mab Biopharma Co Ltd
ImmunityBio Inc
ImmunoGen Inc
IMPACT Therapeutics Inc
IMV Inc
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kyowa Kirin Co Ltd
Leap Therapeutics Inc
Lokon Pharma AB
MabVax Therapeutics Holdings Inc
Mateon Therapeutics Inc
MaxCyte Inc
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Moderna Inc
Mycenax Biotech Inc
Neon Therapeutics Inc
Northlake International LLC
Novartis AG
NuCana Plc
Oasmia Pharmaceutical AB
OBI Pharma Inc
Omnitura Therapeutics Inc
Oncoinvent AS
Oncolix Inc
Oncologie Inc
Oncolytics Biotech Inc
OncoQuest Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Plexxikon Inc
Prestige BioPharma Pte Ltd
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
R-Pharm US LLC
Regeneron Pharmaceuticals Inc
Rgenix Inc
Richter Gedeon Nyrt
Rigel Pharmaceuticals Inc
Samyang Holdings Corp
Sanofi
SELLAS Life Sciences Group Inc
Shenzen SiBiono GeneTech Co Ltd
Sotio AS
Sutro Biopharma Inc
Syndax Pharmaceuticals Inc
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
Tmunity Therapeutics Inc
Transgene SA
Vascular Biogenics Ltd
Verastem Inc
Vyriad Inc
Xcovery Holding Co LLC
Xencor Inc
Zymeworks Inc